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Abstract
Objectives: Recent reports have suggested that Aboriginal and American Indian people are at
elevated risk of HIV infection. We undertook the present study to compare socio-demographic
and risk variables between Aboriginal and non-Aboriginal young (aged 13 – 24 years) injection drug
users (IDUs) and characterize the burden of HIV infection among young Aboriginal IDUs.
Methods: We compared socio-demographic and risk variables between Aboriginal and non-
Aboriginal young IDUs. Data were collected through the Vancouver Injection Drug Users Study
(VIDUS). Semi-annually, participants have completed an interviewer-administered questionnaire
and have undergone serologic testing for HIV and Hepatitis C (HCV).
Results: To date over 1500 Vancouver IDU have been enrolled and followed, among whom 291
were aged 24 years and younger. Of the 291 young injectors, 80 (27%) were Aboriginal. In
comparison to non-Aboriginal youth, Aboriginal youth were more likely to test seropositive for
either HIV (20% vs 7%, p=< 0.001) or Hepatitis C virus (HCV) (66% vs 38%, p =< 0.001), be
involved in sex work and live in the city's IDU epi-centre at baseline. After 48 months of follow-up,
Aboriginal youth experienced significantly higher HIV seroconversion rates than non-Aboriginal
youth, 27.8 per ppy (95% CI: 13.4–42.2) vs. 7.0 per ppy (95% CI: 2.3–11.8) respectively (log-rank p
= 0.005) and the incidence density over the entire follow-up period was 12.6 per 100 pyrs (CI:
6.49–21.96) and 3.9 per 100 pyrs (CI: 1.8–7.3) respectively.
Interpretation: These findings demonstrate that culturally relevant, evidence based prevention
programs are urgently required to prevent HIV infection among Aboriginal youth.
Introduction
In Canada and the United States, the respective Centres
for Disease Control have been alerted to the fact that per-
sons of Aboriginal and American Indian descent may be
at elevated risk for HIV/AIDS [1-3], though little data is
presently available to inform prevention efforts. In the
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province of British Columbia, HIV surveillance data indi-
cated that Aboriginal people accounted for approximately
4% of the total population but comprised 18% of new
HIV infections between 1996 and 2000 [4,5]. It is esti-
mated that nearly half of the urban Aboriginal population
in Canada is under the age of 25 years compared to 30%
of the non-Aboriginal population[6]. To date there has
been little focus on the impact of the HIV/AIDS epidemic
on young Aboriginal peoples and few data are available
regarding risk factors for HIV transmission among Aborig-
inal youth.
Aboriginal people in Canada are overrepresented among
marginalized groups at risk for HIV/AIDS such as injec-
tion drug users (IDU) and street youth, particularly in the
western provinces where a relatively higher proportion of
Aboriginal people reside [2,6]. For example, in the Van-
couver Injection Drug Users Study (VIDUS), Aboriginal
people account for approximately 25% of the 1500 IDU
enrolled[7]. Aboriginal service providers have suggested
that injection drug use may be one of the ways in which
Aboriginal people cope with the complex effects of dis-
crimination, poverty and cultural dislocation, including
the multigenerational effects of the residential school sys-
tem [8].
National Canadian epidemiologic surveillance data sug-
gest that Aboriginal youth may be at particularly high risk
of HIV/AIDS, whereby 33% of newly diagnosed Aborigi-
nal people were under the age of 30 as compared with
20% of non-Aboriginal people[2]. In addition, between
1998 and 2000, 60% of new HIV infections among Abo-
riginal people were attributed to injection drug use[1].
While there has been much literature documenting the
explosive HIV outbreak that occurred among injection
drug users in Vancouver[9], only recently has attention
been paid to the elevated rates of HIV infection among
Aboriginal IDUs[8,10]. However, no studies have specifi-
cally considered HIV prevalence and incidence rates
among Aboriginal youth in this setting. We undertook
this study to compare young Aboriginal IDU and non-
Aboriginal IDU in a city where an explosive and ongoing
HIV epidemic has occurred and where approximately one
quarter of the IDU population are Aboriginal.
Methods
The Vancouver Injection Drug User Study (VIDUS) is a
prospective cohort study of injection drug users who have
been recruited through self-referral and street outreach
from Vancouver's Downtown Eastside since May 1996.
The Downtown Eastside is Vancouver's poorest neighbor-
hood and IDU epi-centre, where an estimated 4,700 IDUs
and 1,000 street youth reside in an area of approximately
ten city blocks, and where inexpensive housing in the
form of hotels and single room occupancy hotels (SROs)
are common. The cohort has been described in detail pre-
viously[9,11,12]. Briefly, persons were eligible for the
VIDUS if they had injected illicit drugs at least once in the
previous month, and resided in the greater Vancouver
region. At baseline and semi-annually, subjects have pro-
vided venous blood samples and completed an inter-
viewer-administered questionnaire. All participants
provided informed consent, and were given a stipend
($20 CDN) at each study visit.
Instrument
The questionnaire elicits demographic data as well as
information about drug use, HIV risk behavior, and the
use of drug treatment. Behavioral variables were elicited at
each semi-annual follow-up visit and are in reference to
the six-month period prior to the interview. Risk factor
variables considered in the present analyses include: sex
work, use of methadone maintenance therapy (MMT), fre-
quency of cocaine and heroin injection, and sexual risk
variables. Sex-work involvement was defined as exchang-
ing sex for money, goods, drugs, shelter, or anything else
during the previous 6 months. Sexual behaviours with
casual and regular sex partners were assessed separately,
and sexual risk was defined as one or more instances of
unprotected vaginal or anal intercourse. Regular partners
were defined as "someone you have had a sexual relation-
ship with for more than three months (not including cli-
ents/tricks)" and casual partners were defined as
"someone you have had a sexual relationship with for less
than three months (not including tricks/clients)". As has
been done previously[13], unstable housing was defined
as living in a single room occupancy hotel, transitional
living arrangements, or homelessness. As previously[11],
frequent cocaine or heroin injection refers to at least daily
use, and frequent crack use refers to at least daily crack
cocaine smoking and we also evaluated alcohol use and
reporting requiring help with injections [14] in the six
months previous to the time of interview. Sexually trans-
mitted infections (STIs) were based on self-report. All
time-updated behavioral variables are elicited in reference
to the six months preceding the interview whereas socio-
demographic covariates (ie gender, ethnicity) were treated
as fixed baseline covariates.
Statistical analysis
The present analyses were restricted to VIDUS participants
aged 24 years and younger who were recruited between
May 1996 and May 2003. As has been done previ-
ously[15], youth were defined as those participants in the
cohort who were ≤24 years at enrolment based on the age
criterion for youth and/or adolescents used in reports on
HIV/AIDS generated by the United Nations, the World
Health Organization, the Centres for Disease Control and
Health Canada. Aboriginal ethnicity was based on self-
report to the question: "are you of First Nation, Aborigi-Harm Reduction Journal 2006, 3:9 http://www.harmreductionjournal.com/content/3/1/9
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nal, Inuit, or Métis origin and/or do you have a status
Indian card issued by the federal government?" For the
purpose of these analyses, all Aboriginal groups were
combined and defined as "Aboriginal" due to the large
number of different Nations comprising Aboriginal
groups in Canada and British Columbia thus presenting
statistical challenges due to power related issues. How-
ever, it is noted that we present data combining individu-
als representing many nations that differ
characteristically, and these differences are not considered
in these analyses.
For the analysis of baseline characteristics and baseline
HIV prevalence, we used contingency table analysis to
compare socio-demographic, HIV serology, and risk factor
variables for Aboriginal and non-Aboriginal youth. Chi-
square and Fischer's exact tests were used to compare
socio-demographic and risk factors among the Aboriginal
and non-Aboriginal youth. We identified characteristics
that were independently associated with Aboriginal youth
by fitting a logistic regression model considering all varia-
bles that were statistically associated with Aboriginal eth-
nicity at the p < 0.05 level in univariate analyses.
Baseline HIV-negative youth with at least one follow-up
visit were eligible for an analysis of the time to HIV infec-
tion. In these analyses, time zero was defined as the date
of enrolment into the study. Participants who did not
become HIV-infected during the follow-up period were
censored as of May 2003 or at the time of their most recent
follow-up prior to this date. Cumulative HIV incidence
rates were calculated using the Kaplan-Meier methods and
HIV-infection rates were compared by the log-rank test.
Cox proportional hazards regression was used to assess
the independent effect of both fixed and time-dependent
covariates on time to HIV seroconversion. In the first mul-
tivariate model, we considered all variables that were sta-
tistically associated with HIV seroconversion at the p <
0.05 level in univariate analyses in a fixed model that
included all of these covariates. Because we were con-
scious that the number of HIV seroconversions was small
and statistical power was limited, we also prepared a par-
simonious model that only included those behavioral var-
iables that remained statistically associated (p  < 0.05)
with HIV seroconversion after adjustment. All statistical
analyses were performed using SAS software version 8.0
(SAS, Cary, NC). All reported p values were 2-sided.
Results
Between May 1996 and May 2003, 1548 participants were
recruited into the VIDUS study among whom there were
291 (19%) participants aged ≤24 years. Overall, 80 (27%)
of the youth were Aboriginal and 211 (73%) were non-
Aboriginal.
As shown in Table 1, there was no statistical difference
between Aboriginal and non-Aboriginal youth with
respect to age [median 16 (IQR: 14–18) vs. 17 (IQR: 15–
19) respectively (p = 0.114)]; however, Aboriginal youth
had, on average, been injecting longer [median number of
years since first injection was 5 (IQR: 2–8) vs. 3 (IQR: 1–
5)] than non-Aboriginal youth (p =< 0.001). Aboriginal
youth were more likely to be female (OR: 2.22 [CI: 1.31–
3.79]), report a history of sexual abuse (OR: 1.78 [CI:
1.06–2.99]), work in the sex trade (OR: 2.90 [CI: 1.70–
4.94]), report a recent STI (OR: 1.73 [CI: 1.03–2.93]) and
Table 1: Comparison of baseline sociodemographic characteristics, drug and sexual risk variables between Aboriginal youth (N = 80) 
and Non-Aboriginal youth (N = 211) aged 24 and under in the VIDUS project.
Aboriginal Youth 
(N = 80, 27%)
Non-Aboriginal Youth 
(N = 211, 73%)
Odds Ratios [95% CI] *p-value
Years Fixing 5 (IQR: 2–8) 3 (IQR: 1–5) ------- <0.001
HIV-positive 16 (20) 20 (7) 4.15 [1.86–9.22] <0.001
HCV-positive 53 (66) 80 (38) 3.21 [1.87–5.52] <0.001
Female 52 (65) 96 (46) 2.22 [1.31–3.79] 0.003
Unstable House 52 (65) 124 (59) 1.30 [0.76–2.22] 0.332
Sex Trade 50 (63) 77 (36) 2.90 [1.70–4.94] <0.001
Sexual Abuse 40 (50) 76 (36) 1.78 [1.06–2.99] 0.029
Condoms w/Regular 17 (21) 34 (16) 1.40 [0.73–2.69] 0.304
Condoms w/Casual 15 (19) 64 (30) 0.53 [0.28–1.00] 0.047
STI 37 (46) 70 (33) 1.73 [1.03–2.93] 0.039
Alcohol Use 34 (43) 88 (42) 1.03 [0.61–1.74] 0.903
≥ 1 Daily Heroin 38 (48) 119 (56) 0.70 [0.42–1.17] 0.174
≥ 1 Daily Cocaine 35 (44) 59 (28) 2.00 [1.17–3.42] 0.010
≥ 1 Daily Crack 16 (20) 26 (12) 1.78 [0.90–3.53] 0.096
Help Injecting 36 (45) 115 (55) 0.68 [0.41–1.15] 0.145
On MMT 0 (0) 7 (3) ----------- 0.099
*All reported p-values are two-sided. STI = sexually transmitted infection, MMT = methadone maintenance therapy.Harm Reduction Journal 2006, 3:9 http://www.harmreductionjournal.com/content/3/1/9
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inject cocaine (OR: 2.00 [CI: 1.17–3.42]) and speedballs
(OR: 2.07 [CI: 1.06–4.02]) on a frequent basis.
There were no differences between Aboriginal and non-
Aborginal groups with respect to alcohol use (OR: 1.03
[CI: 0.61–1.74]), condom use with regular sexual partners
(OR: 1.40 [CI: 0.73–2.69]), crack cocaine use (OR: 1.78
[CI: 0.90–3.53]) or ever accessing methadone mainte-
nance therapy (OR: 0.0 [CI: 0.0–0.0]). Aboriginal youth
were less likely to use condoms with casual sexual part-
ners (OR: 0.53 [CI: 0.28, 1.00]). Of note, at study enroll-
ment, Aboriginal youth were more like to have tested HIV-
positive (OR: 4.15 [95% CI: 1.86–9.22]) and HCV-posi-
tive (OR: 3.21 [CI: 1.87–5.52]).
In the multi-variable analysis that adjusted for all varia-
bles significant in the univariate analysis, independent
associations with Aboriginal ethnicity were HIV positivity
(OR: 2.54 [CI: 1.25–5.16]), HCV positivity (OR: 1.91 [CI:
1.00–3.65]), and sex trade involvement (OR: 2.08 [CI:
1.15–3.77]). Conversely, daily heroin injection was
inversely associated with Aboriginal ethnicity (OR: 0.50
[CI: 0.28–0.91]). The multivariate model was further
adjusted for residing in the Downtown Eastside of Van-
couver (OR; 2.17 [CI: 1.21–3.88]) since this neighbor-
hood is where injection drug use activity is concentrated
and due to the disproportionate number of Aboriginal
peoples residing in this area of Vancouver.
We then examined the time to HIV-infection among Abo-
riginal and non-Aboriginal youth. There were 196 youth
who were HIV negative at enrolment and completed at
least one follow-up visit during the observation period. Of
the 196 youth, 55 (28%) were Aboriginal and 141 (72%)
non-Aboriginal. As of May 31, 2003, HIV seroconversion
had occurred in 21 (11%) of the 196 youth, among whom
12 (22%) were among Aboriginal and 9 (6%) were
among non-Aboriginal youth. As shown in the Kaplan-
Meier analysis (Figure 1) the cumulative HIV incidence
rate after 48 months was 27.8% (95% CI: 13.4–42.2) for
Aboriginal youth vs. 7.0% (CI: 2.3–11.8) for non-Aborig-
inal youth (log-rank p = 0.005) and HIV incidence density
over the entire follow-up period was 12.6% per 100 pyrs
(CI: 6.49–21.96) and 3.9 per 100 pyrs (CI: 1.8–7.3)
respectively.
In univariate Cox regression analyses, factors associated
with HIV seroconversion among the youth were; Aborigi-
nal ethnicity (Relative Hazard [RH]: 3.38 [95%CI: 1.43–
8.03]), unstable housing (RH: 2.59 [CI: 1.00–6.71]), sex
trade (RH: 2.96 [CI: 1.24–7.07]), ≥1 daily heroin injection
(RH: 2.65 [CI: 1.05–6.73]), ≥1 daily cocaine injection
(RH: 5.85 [CI: 2.40–14.30]), and requiring help injecting
(RH: 3.47 [CI: 1.46–8.29]).
In the multi-variable analysis (Table 2), after removing
non-significant (p  > 0.05) behavioral variables, factors
independently associated with HIV seroconversion
among the youth were Aboriginal ethnicity (Adjusted Rel-
ative Hazard [ARH]: 2.46, [CI: 1.00–6.03]) and ≥1 daily
cocaine injection (ARH: 3.88, [CI: 1.54–9.78]).
Discussion
The main finding of this study was that Aboriginal youth
who inject drugs were more than four times as likely to be
HIV-infected at enrolment and were more than twice as
likely to become HIV-infected during follow-up than non-
Aboriginal youth who inject drugs. These data are con-
cerning and corroborate the concerns voiced by many
people in the Aboriginal community as well as Aboriginal
service providers[8]. The exceedingly high HIV incidence
rate of 27.8 per person years among the young Aboriginal
participants indicates that culturally appropriate preven-
tion programs and services that address the health needs
of HIV-positive Aboriginal people are urgently needed.
Aboriginal youth were more likely to inject cocaine on a
daily basis than non-Aboriginal youth. Injection cocaine
use has consistently been found to be a strong independ-
ent risk factor for HIV and HCV infection among
IDUs[16], particularly in this setting[8,11,17]. Aboriginal
youth were more likely to use crack on a daily basis, a
behaviour that has been shown to increase vulnerability
to sexually transmitted infections [18-20].
None of the young Aboriginal injectors had ever accessed
methadone maintenance therapy even though almost half
reported using heroin daily at baseline. Methadone main-
tenance therapy has been shown to aid in risk reduction
among injection drug users[21,22]. Overall, uptake of
Kaplan-Meier product limit cumulative HIV incidence strati- fied by Aboriginal ethnicity Figure 1
Kaplan-Meier product limit cumulative HIV incidence strati-
fied by Aboriginal ethnicity.
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methadone among the young participants is very low sug-
gesting there may be a need to explore reduced access to
methadone treatment services among at risk youth. In the
United States some studies have suggested that African-
American IDU are less likely to be enrolled in methadone
maintenance programs [23-25] which may be due in part
to African American peoples distrust of methadone as a
substance abuse treatment[26]. This finding may also sug-
gest an apprehension among Aboriginal youth to access
treatment services not specifically designed for and in col-
laboration with this population.
Among the Aboriginal youth in this study, 65% were
female, which is disproportionate to other IDU cohort
studies where females tend to comprise approximately
one third of the sample[13,16,27]. The link between
young Aboriginal females and injection drug use in the
present setting requires further investigation; at the very
least, this finding underscores a need for targeted inter-
ventions designed specifically for and in collaboration
with young Aboriginal females. In this study, Aboriginal
youth were more likely to be engaged in sex trade work
and to report a history of sexual abuse, which may be
explained by the higher proportions of females in this
group. However, there remains an urgent need for a cul-
turally appropriate public health response to sexual abuse
survivors and sex work prevention programs for children
as well as programs offering safety to young women
involved in sex work.
Compared to other youth, Aboriginal youth were more
likely to report lower prevalence of condom use with cas-
ual sexual partners and to self-report recently diagnosed
STI's. These findings demonstrate a potential need for
increased awareness regarding the risks of HIV acquisition
from unsafe sex in this population. HIV interventions
among this population will likely need to consider differ-
ential power dynamics between females and males in sex-
ual relationships as well as the effects of discrimination,
the residential school system and cultural dislocation [28-
30].
Several limitations of this study should be acknowledged.
First, as has been previously described, the study popula-
tion was not a random sample of all IDUs and the analy-
ses was primarily based on self-reported behaviours.
However, previous studies in our setting have suggested
the sample is representative of IDUs in the commu-
nity[31]. Nevertheless, due to the small sample size in our
analyses, further studies will be required to confirm the
risk factors associated with HIV seroconversion among
Aboriginal youth. In addition, qualitative studies will
likely be valuable in providing a better understanding of
the HIV-related vulnerabilities that may be unique to
young Aboriginal people.
In summary, we identified exceedingly high baseline HIV
prevalence and subsequent elevated HIV incidence among
young Aboriginal injection drug users. Our study also
highlights the disproportionate number of young female
Aboriginal people using injection drugs and an increased
vulnerability to sex work. Our findings demonstrate the
urgent need for policy-makers, in collaboration with the
affected community, to implement an evidence-based
and culturally appropriate HIV prevention and addiction
treatment strategy to respond to the dual epidemics of
injection drug use and HIV among young Aboriginal drug
users. Ultimately, all service delivery programs including
drug treatment and methadone maintenance therapy,
requires Aboriginal involvement to validate and provide
culturally appropriate assessments of the services offered.
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